TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subpopulations and Intermediate Outcome Measures in COPD Study
Brief Summary: SPIROMICS I and SPIROMICS II are observational studies of Chronic Obstructive Pulmonary Disease (COPD).

SPIROMICS I had two main aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not COPD is getting worse and so provide new ways of testing whether a new treatment is working.

SPIROMICS II has three primary aims. Aim 1 is to define the natural history of "Smokers with symptoms despite preserved spirometry" and characterize the airway mucus abnormalities underlying this condition. Aim 2 is to determine the radiographic precursor lesion(s) for emphysema, and identify the molecular phenotypes underlying airway disease and emphysema. Aim 3 is to advance understanding of the biology of COPD exacerbations through analysis of predisposing baseline phenotypes, exacerbation triggers and host inflammatory response.


Options:
A: Arm Label: Smokers without COPD; Type: N/A; Interventions: N/A | Arm Label: Severe COPD; Type: N/A; Interventions: N/A | Arm Label: Mild/Moderate COPD; Type: N/A; Interventions: N/A | Arm Label: Non-smokers; Type: N/A; Interventions: N/A
B: Arm Label: NHW COPD Participants; Type: N/A; Interventions: N/A | Arm Label: NHW Control Group; Type: N/A; Interventions: N/A | Arm Label: AA COPD Participants; Type: N/A; Interventions: N/A | Arm Label: AA Control Group; Type: N/A; Interventions: N/A
C: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group
D: Arm Label: OM-85; Type: EXPERIMENTAL; Interventions: Drug: OM-85 BV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: OM-85 BV | Intervention Type: DRUG; Name: OM-85 BV; Assigned to Arm(s): OM-85, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Brief Summary: This study was designed in a multicenter, randomized, double-blind, placebo controlled trial to test the actual therapeutic effects of intravesical BoNTA injection. The results of this study might provide clinical evidence for a better therapeutic regimen in the treatment of IC/PBS.


Options:
A: Arm Label: Botulinum toxin A; Type: EXPERIMENTAL; Interventions: Drug: Botulinum toxin A | Arm Label: Control arm-Normal saline instillation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline instillation | Intervention Type: DRUG; Name: Botulinum toxin A; Assigned to Arm(s): Botulinum toxin A | Intervention Type: DRUG; Name: Normal saline instillation; Assigned to Arm(s): Control arm-Normal saline instillation
B: Arm Label: JNJ-42160443; Type: EXPERIMENTAL; Interventions: Drug: JNJ-42160443 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: JNJ-42160443; Assigned to Arm(s): JNJ-42160443
C: Arm Label: Mirabegron; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): Mirabegron | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: Inactive drug; Type: PLACEBO_COMPARATOR; Interventions: Other: inactive drug | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: OTHER; Name: inactive drug; Assigned to Arm(s): Inactive drug

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: College and University Student Intervention to Increase Consent for Organ Donation
Brief Summary: The purpose of this study is to determine the effect of brief organ donation video interventions on consent for organ donation among college and university students. Our hypothesis is that the organ donation video interventions will be superior to lay health websites for increasing organ donation consent.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reception staff providing handout., Behavioral: Mobile Tablet (e.g. iPad) | Intervention Type: BEHAVIORAL; Name: Reception staff providing handout.; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Mobile Tablet (e.g. iPad); Assigned to Arm(s): Intervention
B: Arm Label: TALK Plus; Type: EXPERIMENTAL; Interventions: Behavioral: TALK PLUS | Arm Label: TALK Standard; Type: EXPERIMENTAL; Interventions: Behavioral: TALK Standard | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: TALK PLUS; Assigned to Arm(s): TALK Plus | Intervention Type: BEHAVIORAL; Name: TALK Standard; Assigned to Arm(s): TALK Standard | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: HRSA Video Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: HRSA Video Intervention | Arm Label: PI Video Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PI Video Intervention | Arm Label: CDC Health Website Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CDC Health Website Intervention | Intervention Type: BEHAVIORAL; Name: HRSA Video Intervention; Assigned to Arm(s): HRSA Video Intervention | Intervention Type: BEHAVIORAL; Name: PI Video Intervention; Assigned to Arm(s): PI Video Intervention | Intervention Type: BEHAVIORAL; Name: CDC Health Website Intervention; Assigned to Arm(s): CDC Health Website Intervention
D: Arm Label: Usual education (standard care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intensive initial education; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive initial education | Intervention Type: BEHAVIORAL; Name: Intensive initial education; Assigned to Arm(s): Intensive initial education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AA Linkage for Alcohol Abusing Women Leaving Jail
Brief Summary: The primary aims of this study are to test the hypotheses that among alcohol abusing and dependent jailed women returning to the community, adding an Alcoholic Anonymous (AA) linkage intervention will result in less alcohol use at follow-up, increased AA attendance once released, and decreased HIV/STI sexual risk behavior. Additionally, this study seeks to test the hypotheses that increased AA attendance will mediate the effect of the AA linkage intervention on alcohol use and that percent days abstinent will mediate the effect of the intervention on HIV/STI sexual risk-taking outcomes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
B: Arm Label: Introduction to AA volunteer; Type: OTHER; Interventions: Other: Introduction to AA volunteer | Arm Label: AA materials offered; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Introduction to AA volunteer; Assigned to Arm(s): Introduction to AA volunteer
C: Arm Label: Treatment As Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Enhancement Therapy (MET); Type: EXPERIMENTAL; Interventions: Behavioral: Motivation Enhancement Therapy (MET) | Arm Label: Peer-delivered Twelve Step Facilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-Twelve Step Facilitation (P-TSF) | Intervention Type: BEHAVIORAL; Name: Motivation Enhancement Therapy (MET); Assigned to Arm(s): Motivational Enhancement Therapy (MET) | Intervention Type: BEHAVIORAL; Name: Peer-Twelve Step Facilitation (P-TSF); Assigned to Arm(s): Peer-delivered Twelve Step Facilitation
D: Arm Label: MBRP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Based Relapse Prevention | Arm Label: Relapse Prevention (RP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relapse Prevention | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Relapse Prevention; Assigned to Arm(s): MBRP | Intervention Type: BEHAVIORAL; Name: Relapse Prevention; Assigned to Arm(s): Relapse Prevention (RP) | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
Brief Summary: The proposed project will pilot the use of IGF-1 as a novel treatment for core symptoms of autism. We will use a double-blind, placebo-controlled crossover trial design in five children with autism to evaluate the impact of IGF-1 treatment on autism-specific impairments in socialization, language, and repetitive behaviors. We expect to provide evidence for the safety and feasibility of IGF-1 in ameliorating social withdrawal in children with Autistic Disorder. Further, we expect to demonstrate that IGF-1 is associated with improvement on secondary outcomes of social impairment, language delay, and repetitive behavior, as well as on functional outcomes of global severity.


Options:
A: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
B: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Balovaptan (RO5285119) 10 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Arm Label: Balovaptan (RO5285119) 4 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO5285119; Assigned to Arm(s): Balovaptan (RO5285119) 10 mg/d equivalent, Balovaptan (RO5285119) 4 mg/d equivalent
D: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
Brief Summary: The proposed project will pilot the use of IGF-1 as a novel treatment for core symptoms of autism. We will use a double-blind, placebo-controlled crossover trial design in five children with autism to evaluate the impact of IGF-1 treatment on autism-specific impairments in socialization, language, and repetitive behaviors. We expect to provide evidence for the safety and feasibility of IGF-1 in ameliorating social withdrawal in children with Autistic Disorder. Further, we expect to demonstrate that IGF-1 is associated with improvement on secondary outcomes of social impairment, language delay, and repetitive behavior, as well as on functional outcomes of global severity.


Options:
A: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
C: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Social Skills Focused CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Social Skills focused CBT | Arm Label: Stress Management/Relaxation Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management/relaxation training | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo drug | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: BEHAVIORAL; Name: Social Skills focused CBT; Assigned to Arm(s): Social Skills Focused CBT | Intervention Type: BEHAVIORAL; Name: Stress management/relaxation training; Assigned to Arm(s): Stress Management/Relaxation Training | Intervention Type: DRUG; Name: placebo drug; Assigned to Arm(s): placebo drug

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
Brief Summary: The proposed project will pilot the use of IGF-1 as a novel treatment for core symptoms of autism. We will use a double-blind, placebo-controlled crossover trial design in five children with autism to evaluate the impact of IGF-1 treatment on autism-specific impairments in socialization, language, and repetitive behaviors. We expect to provide evidence for the safety and feasibility of IGF-1 in ameliorating social withdrawal in children with Autistic Disorder. Further, we expect to demonstrate that IGF-1 is associated with improvement on secondary outcomes of social impairment, language delay, and repetitive behavior, as well as on functional outcomes of global severity.


Options:
A: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo
B: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001
D: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
Brief Summary: The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.


Options:
A: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501
B: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
D: Arm Label: BCD-085 Q2W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q2W | Arm Label: BCD-085 Q4W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q4W | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCD-085 Q2W; Assigned to Arm(s): BCD-085 Q2W | Intervention Type: DRUG; Name: BCD-085 Q4W; Assigned to Arm(s): BCD-085 Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
Brief Summary: The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.


Options:
A: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501
B: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
C: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Hospital Patient Information Needs Using a Personal Health Record Portal
Brief Summary: The aim of this study is to evaluate the impact of an inpatient personal health record (PHR) portal intervention within the hospital environment. The intervention hopes to improve patient engagement with their care and to measure patient activation and satisfaction. Additional clinical measure (e.g. number of adverse events that occur during the stay, changes to medication orders, etc.) will also be studied. Characterization of hospital patient and clinician attitudes towards patient engagement will also be formalized.


Options:
A: Arm Label: Online disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Online disease management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Online disease management; Assigned to Arm(s): Online disease management
B: Arm Label: Standard tablet computer; Type: EXPERIMENTAL; Interventions: Other: Standard tablet computer | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Enhanced tablet computer; Type: EXPERIMENTAL; Interventions: Other: Enhanced tablet computer | Intervention Type: OTHER; Name: Standard tablet computer; Assigned to Arm(s): Standard tablet computer | Intervention Type: OTHER; Name: Enhanced tablet computer; Assigned to Arm(s): Enhanced tablet computer
C: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: CCH Model; Type: EXPERIMENTAL; Interventions: Other: Collaborative Connected health, (CCH) | Intervention Type: OTHER; Name: Collaborative Connected health, (CCH); Assigned to Arm(s): CCH Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: OPPC service; Type: EXPERIMENTAL; Interventions: Behavioral: OPPC service | Arm Label: WebChoice IHCA; Type: EXPERIMENTAL; Interventions: Behavioral: WebChoice IHCA | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: OPPC service; Assigned to Arm(s): OPPC service | Intervention Type: BEHAVIORAL; Name: WebChoice IHCA; Assigned to Arm(s): WebChoice IHCA

Answer: B